We're thrilled to be an official media partner for #EBMT26, and we can't wait to be on-site once again, filming our expert video interviews! 🎥🩸
Interested in joining us there or attending virtually?
Click here to register now:
➡️ buff.ly/bWxuru2
#BMTsm #HemOnc #ImmunoOnc @theebmt.bsky.social
Just one week to go until #CART26 kicks off in Palma de Mallorca, Spain, and online!🇪🇸 💻
Hear from the meeting chair, Annalisa Ruggeri, who encourages you to register for this hybrid meeting:
🎥 buff.ly/poXdp9x
Register here:
➡️ buff.ly/LMXQ0qU..
#CARTCell #ImmunoOnc #HemOnc @theebmt.bsky.social
🔍 We are looking for papers!
📩 Submit your latest research in the field of #CancerImmunology #ImmunoOnc
🖊️ Whether it is a Research Article, Short Report or Method, your paper would be suitable!
👉 Find out more details buff.ly/ZDb3rO0
Terence Friedlander, MD, shares 3.5-year #EV103 Cohort K data at #ESMO25 — enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC.
🎥 Watch: buff.ly/kWn5KkI
#UroOnc #UroSoMe #Blcsm #ImmunoOnc #CTSM #TrialUpdate
At #IMS25, we spoke with Lisa Leypoldt, who shared findings from the cytogenetic subgroup analyses of the Phase II GMMG-CONCEPT trial evaluating Isa-KRd in newly diagnosed #myeloma.
Click here to watch:
🎥 buff.ly/Ut0Ne7p
#MMSM #MultipleMyeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky
🎥Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, @HKUniversity, shares highlights from the #MetastaticBreastCancer track at #ESMO25 - including updates from VIKTORIA-1, novel ADCs in #TNBC, and PRO/QoL insights.
Watch here ➡️ buff.ly/E4FLjXD
#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #ESMO25
🎥 Asya Varshavsky-Yanovsky shares insight into a study showing that a high peak in absolute lymphocyte count following cilta-cel infusion in patients with #myeloma predicts for increased risk of delayed neurological toxicities:
👉 buff.ly/MjL0Oku 👈
#CARTcell #MMSM #MultipleMyeloma #ImmunoOnc #IMS25
Charles Geyer, MD, reports #DESTINYBreast05 results in HER2+ early BC.
💊 T-DXd > T-DM1 for iDFS & DFS
🧠 Reduced brain mets risk
⚖️ Manageable safety → potential new SoC
🎥 buff.ly/r3AwOkw
#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #Immunotherapy #HER2 #ESMO25 @myesmo.bsky.social
Recently, Gottfried von Keudell shared the long-term follow-up results from the Phase II ELM-2 study evaluating the efficacy of the bispecific antibody odronextamab in patients with R/R #FollicularLymphoma.
Watch here:
👉 buff.ly/6GUNfkY 👈
#ImmunoOnc #LYMsm #CTSM #TrialUpdate #SOHO2025 #MedSky
The IFNγ-CIITA-MHC II axis modulates melanoma cell susceptibility to NK-cell-mediated cytotoxicity
👉 buff.ly/tJzVEhb
#Melanoma #MELCSM #ImmunoOnc
The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉
We recently had the pleasure of speaking to Helen Parry to find out more about the study:
🎥 buff.ly/j1K0VV8
#CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc
It was fantastic to catch up with @jmikhaelmd.bsky.social at #SOHO2025 to gain insight into areas of consensus & controversy in the current & future management of R/R #MultipleMyeloma!🩸
Watch the interview here:
👉 buff.ly/7AoA6tc 👈
#MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
Shigehira Saji, MD, PhD, shares final OS data from EMERALD in 1L HER2+ #BreastCancer.
💊 Eribulin or taxane + trastuzumab + pertuzumab
📈 Median OS >6 years, similar across arms
🧬 PIK3CA = poor prognosis, no impact on treatment effect
🎥 buff.ly/R9sZAVk
#BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25
#iwAL25 | John DiPersio comments on the challenges of treating T-cell malignancies with bispecific antibody therapy, and shares insights into the development of WU-CART-007, an anti-CD7 allogeneic CAR T-cell product:
🎥 buff.ly/s2zXiCa
#ALLsm #Leusm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
It was fantastic to catch up with the lovely Meral Beksac at #IMS25 to hear about strategies for improving CAR T-cell responsiveness and overcoming resistance in patients with #MultipleMyeloma.
Watch the interview here:
🎥 buff.ly/Rm44VmO
#MMsm #Myeloma #CARTCell #ImmunoOnc #BloodSky #HemeSky
At #ESMO25, Enrique Grande, MD, presents results from the Phase II DISCUS trial in aUC.
💊 3 vs 6 chemo cycles before avelumab maintenance
📈 Similar OS & PFS
💪 Better QoL & fewer toxicities with 3 cycles
🎥 buff.ly/UjqkfNT
@myesmo.bsky.social #BladderCancer #ImmunoOnc #GUcancer #Oncology
In an interview from #IMS25, Doris Hansen of @moffittnews.bsky.social outlined the results from a CIBMTR study assessing the safety and efficacy of cilta-cel in R/R #MultipleMyeloma.💉🩸
Watch here:
👉 buff.ly/fMxLmKd 👈
#IMS25 #MMsm #Myeloma #ImmunoOnc #CARTCell @myeloma-society.bsky.social
We recently caught up with Tycel Phillips of @cityofhope.bsky.social, who discussed progress being made in the development of predictive biomarkers of treatment response that can be used when administering bispecifics, CAR-T, or ADCs in #lymphoma:
🎥 buff.ly/Ho867Db
#LYMsm #ImmunoOnc #BloodSky
To learn about the role of the immune system as a mechanism of resistance to T-cell engagers in #MultipleMyeloma, make sure to watch our recent interview from #IMS25 with Samir Parekh. 🎥🩸
Click here:
👉 buff.ly/VceerXt 👈
#MMsm #Myeloma #HemOnc #ImmunoOnc #BloodSky #HemeSky #MedSky
The removal of the Risk Evaluation and Mitigation Strategy (REMS) program for CAR-T therapy is set to broaden access to CAR-T & cellular therapy outside of academic centers.💉🩸
Learn more about this in our recent interview with Muhammad Bilal Abid of @ttu.edu:
🎥 buff.ly/aPIlWiP
#HemOnc #ImmunoOnc
It was fantastic to catch up with Lorenzo Falchi of @mskcancercenter.bsky.social at #SOHO2025 to hear about the potential of bispecific antibody-based combinations for improving outcomes in patients with follicular #lymphoma.
Watch here: 👉 buff.ly/DDHwjBN
#LYMsm #ImmunoOnc #HemOnc #BloodSky
#iwAL25 | Charlie Craddock answers YOUR transplantation questions in a special Ask the Expert session!
Watch here:
👉 buff.ly/TRqoc4q%F0%9...
#HemOnc #ImmunoOnc #AMLsm #BMTsm #Leusm #BloodSky #HemeSky #MedSky
#IMS25 | Meera Mohan of @medicalcollegeofwi.bsky.social discusses a study investigating outcomes after a limited duration of bispecific antibody therapy in patients with R/R #MultipleMyeloma:
🎥 buff.ly/I3wa6uz
#MMsm #Myeloma #HemOnc #ImmunoOnc #BloodSky #HemeSky @myeloma-society.bsky.social
Thank you to Claudio Cerchione for stopping by at #IMS25 to share insight into the use of anti-CD38–based quadruplet regimens for patients with transplant-ineligible #MultipleMyeloma.🩸
Check out the interview here:
👉 buff.ly/jVocJUD 👈
#MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky
⭐ Jason Mouabbi, MD, of @mdanderson.bsky.social, shares an overview of key studies in breast cancer presented at #ASCO25:
🎥 buff.ly/0IeuM2Z
@ascocancer.bsky.social #BCSM #BreastCancer #CTSM #TrialUpdate #ImmunoOnc
⭐ Fabrice André, MD, PhD, shares KEYNOTE-756 results:
➡️ Adding pembrolizumab to neoadjuvant chemo improved pCR in high-risk ER+/HER2- breast cancer. EFS data pending...
🎥 buff.ly/0R25Yjb
#ESMOBreast25 #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc
At #SOHO2025, Sarah Tasian shared insights into the management of Ph-like ALL, highlighting the move toward an individualized, precision medicine approach.
Watch the interview here:
👉 buff.ly/E837gwk 👈
#ALLsm #Leusm #Leukemia #HemOnc #ImmunoOnc #BloodSky #HemeSky #MedSky
Thank you to the lovely Hang Quach of @unimelb.bsky.social for speaking with us at #IMS25 to share results from part one of the Phase I/II DREAMM-20 trial investigating belantamab in pts with R/R #MultipleMyeloma.🩸
Watch now:
🎥 buff.ly/zBD1MpN
#MMsm #Myeloma #CTSM #TrialUpdate #ImmunoOnc #HemOnc
It's always a pleasure to catch up with Hermann Einsele!😊
At #IMS25, Prof. Einsele outlined ongoing trials in #CARTCell therapy for #MultipleMyeloma.💉🩸
Click here to watch the interview:
👉 buff.ly/Bc1gG2R 👈
#CTSM #ImmunoOnc #MMsm #Myeloma #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social
Want to hear about the safety & efficacy of the CD19-directed CAR-T var-cel (ARI-0001) in patients with CLL or Richter's transformation?💉🩸
Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:
🎥 buff.ly/AnTQebz
#CARTCell #ImmunoOnc #CLLsm #Leusm
